Status:
COMPLETED
Mass Balance Study of TS-142 in Healthy Adult Subjects.
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.
Conditions:
Healthy Male Subjects
Eligibility:
MALE
20-39 years
Phase:
PHASE1
Brief Summary
To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of TS-142 after single oral dose of \[14C\] TS-142 in Japanese healthy male subjects. To assess the safety...
Eligibility Criteria
Inclusion
- Japanese males aged \>=20 and \<40 years at the signing of informed consent
- Subjects whose body mass index (BMI) \>=18.5 and \<25.0 kg/m2 at screening
- Subjects who have no abnormal findings in the physical examination, vital signs, and standard 12-lead ECG in the screening test and the test on the day of admission and the test obtained prior to administration of the investigational drug, and whose clinical test results are within the standard values of the clinical trial site in the screening test and the test on the day of admission. However, if who showed abnormal findings but not clinically significant, they can be enrolled in clinical trials based on comprehensive consideration of medical viewpoints by the principal investigator(s) or subinvestigator(s).
- Subjects who understand, and have willingness and ability to read and sign, the informed consent form
Exclusion
- Subjects who have received a substance labeled with a radioisotope within the last 12 months prior to dosing of the investigational drug
- Subjects who have been exposed to a large amount of radiation for therapeutic or diagnostic reasons (CT scan, stomach X-ray, PET scan etc.) within the last 12 months prior to dosing of the investigational drug
- Occupationally exposed worker in the last 12 months prior to dosing of the investigational drug
- Subjects who have had 3 days or less that one or more spontaneous defecations (defecation that occurs without laxatives, enemas, disimpaction) within 7 days before consent is obtained and during the 7 days until on the day of admission. Those who have diarrhea during the 7 days until on the day of admission
- History of any disease or surgery which have impact on investigational drug absorption such as gastrectomy, gastroenterostomy or bowel resection
- Other protocol defined exclusion criteria could apply
Key Trial Info
Start Date :
April 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 19 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04814771
Start Date
April 19 2021
End Date
May 19 2021
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan